2019
DOI: 10.1055/s-0038-1676581
|View full text |Cite
|
Sign up to set email alerts
|

Sticky Platelet Syndrome: 35 Years of Growing Evidence

Abstract: Since the identification of antithrombin deficiency by Egeberg in 1956, ongoing research in prothrombotic defects continues to progress. Interestingly, past research has predominantly focused on coagulation factors and not on other components of the hemostatic system. The possible role of platelet function defects in the development of thrombotic events was suggested for the first time in the late 1970s, when an increased platelet adhesiveness and aggregation after epinephrine (EPI) and adenosine diphosphate (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(3 citation statements)
references
References 69 publications
0
2
0
Order By: Relevance
“…Our findings could also be related to the sticky platelet syndrome, a thrombophilic qualitative platelet disorder characterized by increased in vitro platelet adhesion and aggregation in response to very low concentrations of the weak platelet agonist ADP and/or epinephrine, and increased risk of arterial ischemic events [ 38 ]. This possibility deserves further investigation.…”
Section: Discussionmentioning
confidence: 99%
“…Our findings could also be related to the sticky platelet syndrome, a thrombophilic qualitative platelet disorder characterized by increased in vitro platelet adhesion and aggregation in response to very low concentrations of the weak platelet agonist ADP and/or epinephrine, and increased risk of arterial ischemic events [ 38 ]. This possibility deserves further investigation.…”
Section: Discussionmentioning
confidence: 99%
“…The most common SPS type is the SPS type II, followed by the SPS type I (approximately 30%). SPS type III is rarely found and diagnosed in only about 1% of SPS patients [35,36]. The different types improve clinically identical and there are no differences in treatment.…”
Section: Methodsmentioning
confidence: 99%
“…The first thrombotic event usually occurs before 40 years of age and without prominent acquired risk factors. Direct genetic background of this inherited thrombophilic disorder is not sufficiently known, but the genetic changes of platelet membrane receptors play a possible role in platelet activation and aggregation (1,2).…”
Section: Introductionmentioning
confidence: 99%